Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

被引：165

作者：

Cheng, Haiying ^{[1
]}

Shcherba, Marina ^{[1
]}

Pendurti, Gopichand ^{[1
]}

Liang, Yuanxin ^{[1
]}

Piperdi, Bilal ^{[1
]}

Perez-Soler, Roman ^{[1
]}

机构：

[1] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, 111 East 210th St, Bronx, NY 10467 USA

来源：

LUNG CANCER MANAGEMENT | 2014年 / 3卷 / 01期

关键词：

D O I：

10.2217/LMT.13.72

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating resistance to EGF receptor tyrosine kinase inhibitors. Targeted agents against the components of this pathway are currently in development and their clinical benefits remain to be defined. This review provides an overview of the pathway dysregulation and novel agents targeting the pathway in lung cancer. In addition, potential predictive biomarkers guiding patient selection for targeted PI3K/AKT/mTOR inhibition is also discussed.

引用

页码：67 / 75

页数：9

共 80 条

[1]

[Anonymous], 2004, CANCER RES, V64, P252

[2]

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors [J].

Bendell, Johanna C. ;

Rodon, Jordi ;

Burris, Howard A. ;

de Jonge, Maja ;

Verweij, Jaap ;

Birle, Diana ;

Demanse, David ;

De Buck, Stefan S. ;

Ru, Qinhua C. ;

Peters, Malte ;

Goldbrunner, Michael ;

Baselga, Jose .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :282-290

[3]

Rapamycin passes the torch: a new generation of mTOR inhibitors [J].

Benjamin, Don ;

Colombi, Marco ;

Moroni, Christoph ;

Hall, Michael N. .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (11) :868-880

[4]

Besse B, 2011, J CLIN ONCOL, V29

[5]

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J].

Beuvink, I ;

Boulay, A ;

Fumagalli, S ;

Zilbermann, F ;

Ruetz, S ;

O'Reilly, T ;

Natt, F ;

Hall, J ;

Lane, HA ;

Thomas, G .

CELL, 2005, 120 (06) :747-759

[6]

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors [J].

Buck, Elizabeth ;

Eyzaguirre, Alexandra ;

Brown, Eric ;

Petti, Filippo ;

McCormack, Siobhan ;

Haley, John D. ;

Iwata, Kenneth K. ;

Gibson, Neil W. ;

Griffin, Graeme .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2676-2684

[7]

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway [J].

Busaidy, Naifa L. ;

Farooki, Azeez ;

Dowlati, Afshin ;

Perentesis, John P. ;

Dancey, Janet E. ;

Doyle, Laurence A. ;

Brell, Joanna M. ;

Siu, Lillian L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (23) :2919-2928

[8]

Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079

[9]

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling [J].

Chaft, Jamie E. ;

Arcila, Maria E. ;

Paik, Paul K. ;

Lau, Christopher ;

Riely, Gregory J. ;

Pietanza, M. Catherine ;

Zakowski, Maureen F. ;

Rusch, Valerie ;

Sima, Camelia S. ;

Ladanyi, Marc ;

Kris, Mark G. .

MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) :485-491

[10]

ClincialTrials. gov, GDC0980

← 1 2 3 4 5 6 7 8 →